[11] Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer:a report from the Australian Ovarian Cancer Study Group [ J]...
[36] Litton JK, Beck JT, Jones JM, et al. Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study[J]. J C...
Accessory male breast cancer (BC) is a rare entity and is associated with poor outcome. We report a 76-year-old patient who was diagnosed with concurrent accessory breast and primary lung cancer, both were positive for somatic BRCA-2 (E1593D) mutation. He received concurrent radiation and ...
BRCA2 mutation in 5 databases and found consistent results that ER-positive tumor rates decreased as the age of onset decreased: < 40 years, 83%; 50–60 years, 79%; and ≥ 60 years, 76%. Among sporadic BC, the proportion of ER-positive tumors increased with age [...
Of the three individuals without BRCA mutations, immunoassay correctly predicted no mutation for BRCA1 in all three, while correctly predicting the absence of a BRCA2 mutation in 2 of three individuals. Conclusions: The positive and negative predictive values for this assay were 89% and 100% ...
Familial breast cancerattributable to inheritance of agermline mutationin thetumor suppressor gene,BRCA2, located on chromosome 13q12-13 Gender, Race, and Age Distribution ▪ Mutations inBRCA2have been described in all races with a prevalence of ≈0.1% ...
mutationBreastcancerSurvivalPrognosticfactorsPloidyIt is not well known to what extent carrying a BRCA2 mutation affects the survival of women with breast cancer and prognostic factors among BRCA2-positive women warrant investigation. Using a record linkage approach we compared the long-term survival in...
In the mutation-positive subgroup, oophorectomy was associated with a large and significant reduction in breast cancer mortality (adjusted HR, 0.30 [95% CI, 0.12-0.75]). The beneficial effect of oophorectomy was much higher for mutation carriers than for noncarriers. Two other recent studies ...
(1.07-1.24) <.001 Breast cancer risk for BRCA2 mutation carriers No breast cancers 302 1499 17 1 [Reference] 5 (1-18) 26 (16-40) 39(25-56) 39 (25-56) 1 breast cancer 495 2675 49 1.53 (0.86-2.70) .15 14 (8-24) 30 (21-41) 55 (44-67) 62 (51-74) ≥2 breast cancers...
2.KaufmanB,ShapiraFrommer R, Schmutzler RK, et al: Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33:244-50, 2015 3. Oza AM, Cibula D, Benzaquen AO, et al: Olaparib combined ...